JHVEphoto / Shutterstock.com
The US Court of Appeals for the Federal Circuit last week reversed a Patent Trial and Appeal Board (PTAB) decision, which found that claims in an OSI Pharmaceuticals patent for cancer treatment were obvious.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at email@example.com
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
US Court of Appeals for the Federal Circuit, Apotex, OSI Pharmaceuticals, patents, IPRs, PTAB, cancer treatment, oncology, Tarceva